United Therapeutics
UTHR
425 hedge funds and large institutions have $8.15B invested in United Therapeutics in 2021 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 150 increasing their positions, 150 reducing their positions, and 28 closing their positions.
100% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 28
15% more funds holding in top 10
Funds holding in top 10: 13 → 15 (+2)
6% more funds holding
Funds holding: 402 → 425 (+23)
1.32% more ownership
Funds ownership: 97.24% → 98.56% (+1.3%)
5% more capital invested
Capital invested by funds: $7.78B → $8.15B (+$362M)
0% more repeat investments, than reductions
Existing positions increased: 150 | Existing positions reduced: 150
37% less call options, than puts
Call options by funds: $46.6M | Put options by funds: $74.3M
Top Buyers
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$140M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$85.9M |
| 3 |
EIP
Epoch Investment Partners
New York
|
+$50.3M |
| 4 |
Two Sigma Advisers
New York
|
+$42.3M |
| 5 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$34.3M |
Top Sellers
| 1 |
PA
Perceptive Advisors
New York
|
-$93.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$68.1M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$65.9M |
| 4 |
SCM
Scopia Capital Management
New York
|
-$48.3M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$42.7M |
UTHR Hedge Fund Activity: Q3 2021 in Review
425 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q3 2021, worth a combined $8.15B — up 4.7% from $7.78B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new UTHR positions and 28 closed out — a net gain of 28 holders — while 150 added to existing stakes and 150 trimmed.
The largest buyer was Deutsche Bank, adding an estimated $140M. The largest seller was Perceptive Advisors, cutting an estimated $93.6M.
- 425 institutional investors held United Therapeutics (UTHR) as of Q3 2021, up from 402 in Q2 2021.
- Funds reported $8.15B of United Therapeutics stock for Q3 2021, up 4.7% quarter-over-quarter.
- 56 funds opened new United Therapeutics positions in Q3 2021 and 28 closed out, a net change of +28 holders.
- The largest United Therapeutics buyer in Q3 2021 was Deutsche Bank, an estimated $140M added.
- The largest United Therapeutics seller in Q3 2021 was Perceptive Advisors, an estimated $93.6M sold.
Based on aggregated 13F filings for Q3 2021.